Plus Therapeutics is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of treatments for patients battling cancer and other life-threatening diseases. Co.'s main radiotherapeutic candidate, Rhenium-186 NanoLiposome is designed to target central nervous system cancers including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers by direct localized delivery utilizing approved standard-of-care tissue access. Co.'s radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere is designed to treat various solid organ cancers including primary and secondary liver cancers. We show 20 historical shares outstanding datapoints in our PSTV shares outstanding history coverage, used to compute PSTV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PSTV market cap history over the course of time is important for investors
interested in comparing PSTV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PSTV versus a peer is one thing; comparing
PSTV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PSTV can fluctuate over the course of history.
With this page we aim to empower investors researching PSTV by allowing them to research the PSTV market cap history. |
Free PSTV Email Alerts:
Video: The Importance of Market Cap
